Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has announced the completion of the 25% upfront payment for its preferential issue of 77,02,182 warrants. The aggregate amount received from the allottees (Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP) amounts to ₹1,499,999,944.50. This marks a significant step in the preferential issue process, with the remaining 75% of the issue price due upon warrant conversion.
KIMS Hospitals Confirms Partial Warrant Payment
Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has officially informed the stock exchanges about the completion of the initial payment phase for its preferential issue of warrants. The company has received ₹1,499,999,944.50, representing 25% of the total subscription amount for the allotment of 77,02,182 warrants on a preferential basis.
Allottees and Subscription Details
The warrants have been allotted to key individuals and entities within the promoter group: Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP. The preferential issue aims to raise capital and strengthen the promoter group’s holding in the company. The total subscription amount received signifies a substantial financial commitment towards the warrant issuance.
Warrant Conversion and Future Steps
The issued warrants are convertible into equity shares of the Company within a period of 18 months from the allotment date. The remaining 75% of the issue price will be payable by the warrant holders at the time of exercising their right to convert these warrants into equity shares. KIMS Hospitals will also undertake the necessary steps for the listing and trading of equity shares upon conversion.
Shareholding Impact
Post-allotment and assuming full conversion of warrants, the shareholding of the promoter and promoter group is projected to increase from 32.50% to 33.71%. This indicates a strategic move to consolidate and potentially increase ownership by the promoter entities. The paid-up equity share capital of the Company remains unchanged as of this announcement, as the warrants are convertible at a later date.
Auditor’s Certification
An Independent Auditor’s Report from S.R. Batliboi & Associates LLP has been provided, certifying the receipt of consideration for the specified securities in connection with the preferential issue as per the SEBI ICDR Regulations. The auditor’s examination confirmed that the details provided in the statement are in accordance with the requirements and relevant documents are maintained by the Company as of August 19, 2026.
Source: BSE
